Immune-Onc Therapeutics company information, Employees & Contact Information

Targeted Vaccine Leads to Broad Immune Response in Pancreatic Cancer Targeted Oncology

First Patient Dosed With IO-108 in Phase 1b/2 HCC Trial Targeted Oncology

Immune-Onc doses first subject in trial of IO-108 for HCC Clinical Trials Arena

ICIs Effective Regardless of Patients' Age, But Key Immune Phenotype Differences May Enable Tailored Regimens Targeted Oncology

Immune-Onc Therapeutics, Inc. Announces $7 Million Series A Financing PR Newswire

Pancreatic Cancer Vaccine Aims For New Approach to Preventing Recurrence Targeted Oncology

Real-World Retrospective Study Confirms Efficacy, Safety of Neoadjuvant ICIs in dMMR/MSI Nonmetastatic Colon Cancer Targeted Oncology

Bel-Sar Shows Promising Clinical and Immune Activity in NMIBC Targeted Oncology

FDA Clears Novel Cancer Immunotherapy R-5780 for Early-Stage Trial Targeted Oncology

TNBC Vaccine Shows Promising Safety, Immune Response in Phase 1 Trial Targeted Oncology

Novel METTL3 Inhibitor Elicits Clinical Activity Across Tumor Types Targeted Oncology

Ibrutinib Single-handedly Impacts Immune Environment in Metastatic PDAC Targeted Oncology

IO-202 Receives FDA Orphan Drug Designation in CMML Targeted Oncology

CAN-2409/Vancyclovir Leads to Positive Tolerability, Immune Response in NSCLC Targeted Oncology

Broad Immune Activity Is Observed With Sotigalimab Combo in Frontline Melanoma Targeted Oncology

Immune Checkpoint Inhibitors in Bladder Cancer: Refining Their Role Targeted Oncology

Immunotherapy Opens a “New Era” in Treating T-Cell Malignancies Targeted Oncology

Overview of Immune Checkpoint Inhibitors in NSCLC Targeted Oncology

CAN-2409 Shows Strong OS Outcomes in ICI-Refractory NSCLC Targeted Oncology

Second-Line Considerations After Immune Toxicity From Prior RCC Therapy Targeted Oncology

Pembrolizumab Plus Denileukin Diftitox Shows Promise in Solid Tumors Targeted Oncology

RP1 and the Future of Oncolytic Therapy in Melanoma Targeted Oncology

Long-Term Immune Checkpoint Inhibition Shows Potential Extended Survival in NSCLC Targeted Oncology

Zanzalintinib/Atezolizumab Improves CRC Survival, Expands TKI's Role in Solid Tumors Targeted Oncology

10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomes Targeted Oncology

Poll: Vote on the Top GU Cancer Abstracts to Watch at ESMO 2025 Targeted Oncology

Immunotherapies Spark Excitement in Triple-Negative Breast Cancer Treatment Targeted Oncology

Update Confirms 5-Year Survival Benefit With Dual Immune Checkpoint Blockade in NSCLC Targeted Oncology

ICT01 Boosts AML Remission and Survival in EVICTION Trial Targeted Oncology

FDA ODAC Finds Limited Benefit for Checkpoint Inhibitors in Low PD-L1 Gastric Cancer Targeted Oncology

The BOT/BAL Breakthrough: A New Era for Colorectal Cancer Treatment Targeted Oncology

IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia OncLive

VISTA Emerges as a Promising Immunotherapy Target in Cancer Targeted Oncology

First Patient Dosed With INKmune Therapy in Phase 1/2 Trial for mCRPC Targeted Oncology

Bridging the Gap Between Oncology and Rheumatology Targeted Oncology

PD-L1 Status Shapes Choice of Using Nivolumab in Upper GI Cancer Targeted Oncology

The Promise of OBX-115, a Novel TIL Therapy, in Melanoma Targeted Oncology

Immune Checkpoint Inhibitor Combinations Play Important Role in Metastatic RCC Targeted Oncology

Efficacy, Safety Observed With Immunotherapy in Patients With HIV Targeted Oncology

Cell Therapies Emerge for the Treatment of Acute Myeloid Leukemia Targeted Oncology

Anti-TIGIT and ICI Combinations Supported by Early-Phase Research Targeted Oncology

Adagrasib/Pembrolizumab Promising in KRAS G12C-Mutated NSCLC Targeted Oncology

Role of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Oncogenic Driver Mutations Targeted Oncology

Largest Study of Black Patients With Cancer Aims to Show Better Responses to Immunotherapy Targeted Oncology

Approaching Treatment for a Patient With NSCLC and an EGFR Mutation Targeted Oncology

A Closer Look at the Most Recent NCCN Guidelines for Bladder Cancer Targeted Oncology

I-SPY2.2: A Personalized Medicine Trial for Neoadjuvant Breast Cancer Treatment Targeted Oncology

Breaking Down MATTERHORN: Durvalumab Plus FLOT in Gastric Cancer Targeted Oncology

New Clues to Pancreatic Cancer Subtypes' Unique Vulnerabilities Targeted Oncology

FDA Grants Fast Track Designation to Rilzabrutinib for Treatment of Immune Thrombocytopenia Targeted Oncology

KEYNOTE-689 Leads to FDA Approval of Perioperative Pembrolizumab in HNSCC Targeted Oncology

Multiple Myeloma: Top 10 Advances in the Past 10 Years Targeted Oncology

Tumor Antigens and Their Role in Immune Response in Melanoma Targeted Oncology

First-Line Treatment Options for Metastatic Squamous Cell NSCLC Targeted Oncology

A Case of Immune Thrombocytopenia Targeted Oncology

Weight May Affect Toxicity of Immunotherapies Targeted Oncology

Autoimmunity and Limitations of Cancer Vaccines Targeted Oncology